A pseudo-randomised clinical trial of in situ gels of fluconazole for the treatment of oropharngeal candidiasis

Trials

Volumn 12, Issue , 2011, Pages

  Nairy, Harish M ^a   Charyulu, Narayana R ^a   Shetty, Veena A ^b   Prabhakara, Prabhu ^a  

^a NITTE DEEMED TO BE UNIVERSITY   (India)

^b NITTE DEEMED TO BE UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE; FLUCONAZOLE; GELLAN; ANTIFUNGAL AGENT;

ABDOMINAL PAIN; ADULT; AIDS RELATED COMPLEX; ARTICLE; CANDIDA; CLINICAL ARTICLE; CONTROLLED STUDY; DENTURE; DIARRHEA; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN SITU GEL; MALE; MULTICENTER STUDY; NAUSEA; OPPORTUNISTIC INFECTION; OROPHARYNX CANDIDIASIS; SINGLE BLIND PROCEDURE; STUDY DESIGN; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; THRUSH;

ADULT; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; FEMALE; FLUCONAZOLE; GELS; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD;

EID: 79956004885     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-99     Document Type: Article

References (11)

1. Murray PA, Koletar SL, Jane Wu IM, Moskovitz BL. Itraconazole Oral Solution Versus Clotrimazole Troches for the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients. Clin Ther 1997, 19:471-80. 10.1016/S0149-2918(97)80131-2, 9220211.
2. Munoz PF-TC, Alcala L, Rodriguez-Creixems M, Pelaez T, Bouza E. Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole. Diagn Microbiol Infect 2002, 44:163-7.
3. Waltimo TM, Orstavik D, Meurman JH, Samaranayake LP, Haapasalo MP. In vitro susceptibility of Candida albicans isolates from apical and marginal periodontitis to common antifungal agents. Oral Microbiol Immunol 2000, 15:245-248. 10.1034/j.1399-302x.2000.150406.x, 11154410.
4. Susan B. Merck Index 1996, 698. Whitehouse Station, NJ: Merck & Co, Inc, 12.
5. Pappas PG, Rex JH, Sobel JD. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-89. 10.1086/380796, 14699449.
6. Bensadoun RJ, Daoud J, Gueddari E, Bastit L, Gourmet R, Rosikon A, Allavena C, Ceruse P, Calais G, Attali P. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 2008, 112:204-11. 10.1002/cncr.23152, 18044772.
7. Charyulu NR, Harish NM, Gulzar MA, Prabhu P, Singh AK, Subrahmanyam EVS. Formulation and In Vitro Evaluation of In Situ Gels Containing Secnidazole for Vaginitis. Yakugaku Zadussi 2009, 129:569-574.
8. Choi BY, Park HJ, Hwang SJ, Park JB. Biological interactions between divalent cation and polysaccharides. Int J Pharm 2002, 239:81-91. 10.1016/S0378-5173(02)00054-6, 12052693.
9. Kedzierewicz F, Lombry C, Rios R, Hoffman M, Maincent P. Effect of the formulation on the in vitro release of propranolol from gellan beads. Int J Pharm 1999, 178:129-136. 10.1016/S0378-5173(98)00351-2, 10205633.
10. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients with human immunodeficiency virus. Antimicrob Agents Chemothe 1990, 34:2267-2268.
11. Patricia AM, Susan LK, Irma M, Jane W, Bruce LM. Itraconazole Oral Solution Versus Clotrimazole Troches for the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients. Clin Ther 1997, 19(3):471-480. 10.1016/S0149-2918(97)80131-2, 9220211.